Open AccessNew‐onset posttransplant diabetes mellitus after haploidentical hematopoietic cell transplantation with posttransplant cyclophosphamide
Author(s) -
Mangan Brendan L.,
Patel Dilan,
Chen Heidi,
Gatwood Katie S.,
Byrne Michael T.,
Sengsayadeth Salyka,
Goodman Stacey,
Dholaria Bhagirathbhai,
Kassim Adetola A.,
Jagasia Madan,
Chinratanalab Wichai,
Culos Kathryn A.,
Engelhardt Brian G.
Publication year - 2020
Publication title -
ejhaem
Language(s) - English
Resource type - Journals
ISSN - 2688-6146
DOI - 10.1002/jha2.70
Subject(s) - medicine , diabetes mellitus , transplantation , cyclophosphamide , incidence (geometry) , hematopoietic cell , gastroenterology , hematopoietic stem cell transplantation , haematopoiesis , surgery , chemotherapy , endocrinology , stem cell , biology , physics , optics , genetics
Abstract Haploidentical hematopoietic cell transplantation (haplo‐HCT) with posttransplant cyclophosphamide (PTCY) is utilized for patients with hematological disorders but without conventional donors. The effects of new‐onset posttransplant diabetes mellitus (PTDM) following haplo‐HCT are unknown. We examined PTDM incidence and outcomes after haplo‐HCT with PTCY. Patients without diabetes receiving haplo‐HCT (n = 64) were analyzed for PTDM diagnosis (defined as blood glucose ≥ 200 mg/dL). By day 100, 14 (22%) patients developed PTDM (median, 18 days). Hyperglycemia (blood glucose ≥ 200 mg/dL) preceded corticosteroids in 11 (79%) individuals. PTDM patients had increased death/relapse ( P = .029). PTDM occurs frequently, precedes corticosteroids, and leads to inferior outcomes following haplo‐HCT. PTDM prophylaxis/treatment may improve HCT survival.